Meanwhile, lumbrokinase inactivated NF-κB signaling, reduced the translocation of p50/p65 into the nucleus and their binding at the COX-2 promoter region, and restrained the transcription of COX-2, thereby enhancing the anti-tumor effect of chemotherapeutics. The gene discussed is NFKB1; the disease is neoplasm.